Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who understand and are willing to give informed consent to participate in the trial.~* Adult male and female subjects between 18 years to 65 years of age with a BMI ≥ 27 kg/m2 ≤ 40 kg/m2, inclusively.~* Subjects with established type 2 diabetes mellitus of at least 3 months duration at the time of screening.~* Subjects with an inadequate glycemic control defined by an HbA1c level of ≥ 7.5% and ≥10% at screening.~* Subjects who are on a stable dose of:~  * Metformin (up to 2.55 gm/day or maximum tolerated dose of at least 1 gm/day) and/or~ * Sulfonylurea (glimepiride ≤ 4 mg/day, gliclazide ≤ 160 mg, glibenclamide or glyburide ≤ 10 mg and glipizide ≤ 10 mg), for ≤ 2 months prior to the screening visit.~* Subjects with fasting plasma glucose of ≤14.4 mmol/L (260 mg/dL) and at least 5.5 mmol/L or 100 mg/dL.~Exclusion Criteria:~* Subjects who have type 1 diabetes mellitus, maturity-onset diabetes of the young or any rare form of diabetes. Subjects with hyperglycemia due to secondary causes.~* Subjects who have had more than 4 episodes of severe hypoglycemia in the 6 months prior to screening.~* Subjects with a history of acute diabetic complications~* Subjects who have been treated with insulin (except for use of insulin for short term management of acute conditions), thiazolidinediones, dual proliferator activated receptors agonists, glucagon-like peptide analogues, dipeptidyl peptidase inhibitors or 11bHSD-1 inhibitors in any form, in the 3 months prior to screening.~* Subjects who are receiving systemic glucocorticoids (≥14 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- P2202 (Type: ACTIVE_COMPARATOR): Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo
- Placebo (Type: PLACEBO_COMPARATOR): Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).